Neoadjuvant Pembrolizumab Achieves 71% pCR in Resectable Desmoplastic Melanoma
Phase 2 SWOG S1512 trial shows neoadjuvant pembrolizumab achieved 71% pathologic complete response in resectable desmoplastic melanoma with 3-year survival rates of 74% for relapse-free and 87% for overall survival.